-
Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells.
Journal of applied toxicology : JAT 20160901
-
Allopurinol and oxypurinol promote osteoblast differentiation and increase bone formation.
Experimental cell research 20160315
-
Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats.
Chemico-biological interactions 20150725
-
Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
Seminars in arthritis and rheumatism 20130601
-
Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of febuxostat in dog plasma and its application to a pharmacokinetic study.
Biomedical chromatography : BMC 20130201
-
Xanthine oxidase inhibitor febuxostat as a novel agent postulated to act against vascular inflammation.
Anti-inflammatory & anti-allergy agents in medicinal chemistry 20130101
-
Isocytosine-based inhibitors of xanthine oxidase: design, synthesis, SAR, PK and in vivo efficacy in rat model of hyperuricemia.
Bioorganic & medicinal chemistry letters 20121215
-
The rheumatology of gout.
Advances in chronic kidney disease 20121101
-
Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress.
Biochemical and biophysical research communications 20121019
-
Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
Seminars in arthritis and rheumatism 20121001
-
Pharmacokinetics of febuxostat in healthy Chinese volunteers.
Arzneimittel-Forschung 20121001
-
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate.
British journal of clinical pharmacology 20120801
-
Payer decision-making with limited comparative and cost effectiveness data: the case of new pharmacological treatments for gout.
Evidence-based medicine 20120801
-
Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy.
Clinical and experimental nephrology 20120801
-
[Gout and other crystal-induced arthritides].
Deutsche medizinische Wochenschrift (1946) 20120801
-
Casebook consults: improving outcomes in gout (multimedia activity).
The American journal of medicine 20120801
-
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
American heart journal 20120701
-
Pegloticase for treating refractory chronic gout.
Drugs of today (Barcelona, Spain : 1998) 20120701
-
Recent advances in management of gout.
QJM : monthly journal of the Association of Physicians 20120501
-
Identification of novel isocytosine derivatives as xanthine oxidase inhibitors from a set of virtual screening hits.
Bioorganic & medicinal chemistry 20120501
-
The effects of xanthine oxidase inhibition by febuxostat on the pharmacokinetics of theophylline.
International journal of clinical pharmacology and therapeutics 20120501
-
[Gout: an overview of available urate lowering therapies].
Annales pharmaceutiques francaises 20120501
-
Gout and organ transplantation.
Current rheumatology reports 20120401
-
[Medication of the month. Febuxostat (Adenuric)].
Revue medicale de Liege 20120401
-
Hyperuricemia, gout and the kidney.
Current opinion in rheumatology 20120301
-
Febuxostat hypersensitivity.
The Journal of rheumatology 20120301
-
[Pharmacological sheet. Febuxostat, oral (Adenuric)].
Journal de pharmacie de Belgique 20120301
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
Arthritis care & research 20120201
-
Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
The Medical journal of Malaysia 20120201
-
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease.
Rheumatology international 20120101
-
An update on the pathology and clinical management of gouty arthritis.
Clinical rheumatology 20120101
-
Can racial disparities in optimal gout treatment be reduced? Evidence from a randomized trial.
BMC medicine 20120101
-
African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
BMC musculoskeletal disorders 20120101
-
Gout and the risk for incident heart failure and systolic dysfunction.
BMJ open 20120101
-
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
BMC geriatrics 20120101
-
Different inhibitory potency of febuxostat towards mammalian and bacterial xanthine oxidoreductases: insight from molecular dynamics.
Scientific reports 20120101
-
Redox proteomics identification of oxidatively modified myocardial proteins in human heart failure: implications for protein function.
PloS one 20120101
-
Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique.
Journal of pharmaceutical and biomedical analysis 20111205
-
[Treatment of gout].
La Revue de medecine interne 20111201
-
Comorbidities in gouty arthritis.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20111201
-
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Deutsche medizinische Wochenschrift (1946) 20111201
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Nucleosides, nucleotides & nucleic acids 20111201
-
2011 Recommendations for the diagnosis and management of gout and hyperuricemia.
Postgraduate medicine 20111101
-
2011 recommendations for the diagnosis and management of gout and hyperuricemia.
The Physician and sportsmedicine 20111101
-
Management of gout in the older adult.
The American journal of geriatric pharmacotherapy 20111001
-
Catastrophic axial gout causing paraplegia in a patient with glycogen storage disease.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20111001
-
Efficacy and safety of febuxostat in patients with hyperuricemia and gout.
Therapeutic advances in musculoskeletal disease 20111001
-
[New therapeutic options for gout].
Presse medicale (Paris, France : 1983) 20110901
-
Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
The Journal of rheumatology 20110901
-
Nickel-catalyzed C-H arylation of azoles with haloarenes: scope, mechanism, and applications to the synthesis of bioactive molecules.
Chemistry (Weinheim an der Bergstrasse, Germany) 20110829
-
Gout and transplantation: new treatment option-same old drug interaction.
Transplantation 20110815
-
Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates.
Journal of cardiovascular translational research 20110801
-
Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.
Clinical journal of the American Society of Nephrology : CJASN 20110801
-
The challenges of gout management in the elderly.
Drugs & aging 20110801
-
[Gout - regardless of therapeutic options a 'forgotten' disease].
Deutsche medizinische Wochenschrift (1946) 20110801
-
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
Annals of the rheumatic diseases 20110701
-
Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production.
Free radical biology & medicine 20110701
-
Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
The Journal of rheumatology 20110701
-
[Febuxostat].
Deutsche medizinische Wochenschrift (1946) 20110601
-
Febuxostat efficacy in allopurinol-resistant tophaceous gout.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
A repeated oral administration study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with impaired renal function in Japan: pharmacokinetic and pharmacodynamic study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110601
-
Managing your patient with gout: a review of treatment options.
Postgraduate medicine 20110501
-
Febuxostat methanol solvate.
Acta crystallographica. Section E, Structure reports online 20110501
-
Developing potent human uric acid transporter 1 (hURAT1) inhibitors.
Journal of medicinal chemistry 20110428
-
Febuxostat for treatment of chronic gout.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110301
-
Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.
Journal of clinical pharmacology 20110201
-
Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
PharmacoEconomics 20110201
-
Gout therapeutics: new drugs for an old disease.
Lancet (London, England) 20110108
-
Renal function in gout: long-term treatment effects of febuxostat.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 20110101
-
Treatment of gout.
Internal medicine journal 20110101
-
A case series of allopurinol-induced toxic epidermal necrolysis.
Indian journal of dermatology 20110101
-
Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.
Case reports in medicine 20110101
-
Renal co-morbidity in patients with rheumatic diseases.
Arthritis research & therapy 20110101
-
The Relation between Fructose-Induced Metabolic Syndrome and Altered Renal Haemodynamic and Excretory Function in the Rat.
International journal of nephrology 20110101
-
Multiarticular chronic tophaceous gout with severe and multiple ulcerations: a case report.
Journal of medical case reports 20110101
-
Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.
PloS one 20110101
-
The role of the NLRP3 inflammasome in gout.
Journal of inflammation research 20110101
-
Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus.
PloS one 20110101
-
Calciphylaxis presenting in early chronic kidney disease with mixed hyperparathyroidism.
International journal of nephrology and renovascular disease 20110101
-
Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.
Journal of blood medicine 20110101
-
[Current management of gout].
Acta medica portuguesa 20110101
-
Febuxostat: a novel agent for management of hyperuricemia in gout.
Indian journal of pharmaceutical sciences 20110101
-
Crystal arthropathies: recognizing and treating 'the gouch'.
Primary care 20101201
-
Managing gout: how is it different in patients with chronic kidney disease?
Cleveland Clinic journal of medicine 20101201
-
Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
Clinical therapeutics 20101201
-
[Therapy of acute gout attack. It need not always be NSAID].
MMW Fortschritte der Medizin 20101125
-
The current state of care in gout: Addressing the need for better understanding of an ancient disease.
Journal of the American Academy of Nurse Practitioners 20101101
-
Febuxostat, a nonpurine selective inhibitor of xanthine oxidase: a promising medical therapy for chronic heart failure?
Chinese medical journal 20100901
-
International position paper on febuxostat.
Clinical rheumatology 20100801
-
Managing gout in the primary care setting: what you and your patients need to know.
The American journal of medicine 20100801
-
Febuxostat for gout.
Drug and therapeutics bulletin 20100701
-
Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
British journal of clinical pharmacology 20100701
-
Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitors.
European journal of medicinal chemistry 20100601
-
High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up.
Diabetes care 20100601
-
Urate-lowering therapy for gout: focus on febuxostat.
Pharmacotherapy 20100601
-
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.
Nucleosides, nucleotides & nucleic acids 20100601
-
New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond.
Current rheumatology reports 20100401
-
Progress in the pharmacotherapy of gout.
Current opinion in rheumatology 20100301
-
Febuxostat provides new gout treatment option.
The Nurse practitioner 20100301
-
Update on gout and hyperuricemia.
International journal of clinical practice 20100201
-
New Drugs2010, PART 1.
Nursing 20100201
-
Update on gout: new therapeutic strategies and options.
Nature reviews. Rheumatology 20100101
-
Management of hyperuricemia in gout: focus on febuxostat.
Clinical interventions in aging 20100101
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
Arthritis research & therapy 20100101
-
[The clinical picture of gout is changing].
Duodecim; laaketieteellinen aikakauskirja 20100101
-
Advances in gout: some answers, more questions.
Arthritis research & therapy 20100101
-
New advances in the treatment of gout: review of pegloticase.
Therapeutics and clinical risk management 20100101
-
[Gout and comorbidities associated with hyperuricemia].
Annales Academiae Medicae Stetinensis 20100101
-
Advances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.
International journal of nephrology and renovascular disease 20100101
-
New and improved strategies for the treatment of gout.
International journal of nephrology and renovascular disease 20100101
-
[Crystal-induced activation of the inflammasome: gout and pseudogout].
Zeitschrift fur Rheumatologie 20091101
-
Approach to the treatment of hyperuricemia.
Medicine and health, Rhode Island 20091101
-
Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Clinical therapeutics 20091101
-
2-[3-Cyano-4-(2-methyl-prop-oxy)phen-yl]-4-methyl-thia-zole-5-carboxylic acid pyridine solvate.
Acta crystallographica. Section E, Structure reports online 20091101
-
Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Health technology assessment (Winchester, England) 20091001
-
Gout Study Group: update on hyperuricemia and gout.
Joint, bone, spine : revue du rhumatisme 20090701
-
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
The Journal of rheumatology 20090601
-
Gout--what are the treatment options?
Expert opinion on pharmacotherapy 20090601
-
Febuxostat (Uloric) for chronic treatment of gout.
The Medical letter on drugs and therapeutics 20090518
-
Febuxostat: a new treatment for hyperuricaemia in gout.
Rheumatology (Oxford, England) 20090501
-
Nickel-catalyzed biaryl coupling of heteroarenes and aryl halides/triflates.
Organic letters 20090416
-
A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout.
Current rheumatology reports 20090401
-
New gout treatment approved.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090401
-
Febuxostat: a new agent for lowering serum urate.
Drugs of today (Barcelona, Spain : 1998) 20090401
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20090401
-
Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire international 20090401
-
Febuxostat treatment for gout: what the clinician needs to know.
Therapeutic advances in musculoskeletal disease 20090401
-
Febuxostat.
Nature reviews. Drug discovery 20090301
-
Update on emerging urate-lowering therapies.
Current opinion in rheumatology 20090301
-
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
Rheumatology (Oxford, England) 20090201
-
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress.
Vascular health and risk management 20090101
-
New drugs: Febuxostat, lacosamide, and rufinamide.
Journal of the American Pharmacists Association : JAPhA 20090101
-
Gout. Novel therapies for treatment of gout and hyperuricemia.
Arthritis research & therapy 20090101
-
Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?
Arthritis research & therapy 20090101
-
The role of urate and xanthine oxidase in vascular oxidative stress: future directions.
Therapeutics and clinical risk management 20090101
-
Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.
Core evidence 20090101
-
Febuxostat in the management of hyperuricemia and chronic gout: a review.
Therapeutics and clinical risk management 20081201
-
Gout management: let's get it right this time.
Arthritis and rheumatism 20081115
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Arthritis and rheumatism 20081115
-
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.
Journal of cardiac failure 20081101
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20081001
-
The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Journal of clinical pharmacology 20080901
-
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
Nucleosides, nucleotides & nucleic acids 20080601
-
In vitro drug-drug interaction studies with febuxostat, a novel non-purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic enzymes and cytochrome P450 inhibition.
Xenobiotica; the fate of foreign compounds in biological systems 20080501
-
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20080401
-
Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome.
American journal of physiology. Renal physiology 20080401
-
[Inhibitors of xanthine oxidoreductase].
Nihon rinsho. Japanese journal of clinical medicine 20080401
-
[New antihyperuricemic medicine: febuxostat, Puricase, etc].
Nihon rinsho. Japanese journal of clinical medicine 20080401
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20080401
-
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
British journal of clinical pharmacology 20080301
-
Refractory gout: what is it and what to do about it?
Current opinion in rheumatology 20080301
-
Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Life sciences 20080227
-
Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi 20080201
-
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia.
Nephron. Physiology 20080101
-
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Drug safety 20080101
-
Febuxostat.
Drugs 20080101
-
Febuxostat: a viewpoint by H. Ralph Schumacher Jr and Lan X. Chen.
Drugs 20080101
-
Febuxostat : a viewpoint by Naomi Schlesinger.
Drugs 20080101
-
Febuxostat : a viewpoint by N. Lawrence Edwards.
Drugs 20080101
-
Developments in the scientific and clinical understanding of gout.
Arthritis research & therapy 20080101
-
Assessment of outcome in clinical trials of gout--a review of current measures.
Rheumatology (Oxford, England) 20071201
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20071201
-
[Crystal-induced arthritis--old but important].
Zeitschrift fur Rheumatologie 20070701
-
Tumor lysis syndrome.
Seminars in thrombosis and hemostasis 20070601
-
Uricase and other novel agents for the management of patients with treatment-failure gout.
Current rheumatology reports 20070601
-
Emerging therapies in the long-term management of hyperuricaemia and gout.
Internal medicine journal 20070401
-
Therapeutic advances in gout.
Current opinion in rheumatology 20070301
-
Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
Recent patents on inflammation & allergy drug discovery 20070201
-
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
International journal of medical sciences 20070101
-
Hyperuricemia and gout: new insights into pathogenesis and treatment.
Bulletin of the NYU hospital for joint diseases 20070101
-
Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
The Annals of pharmacotherapy 20061201
-
Case 8: initiation of urate-lowering therapy for standard advanced gout.
The American journal of medicine 20061101
-
Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure.
Journal of cardiovascular pharmacology 20061101
-
Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness.
International journal of clinical practice 20061001
-
[Febuxostat versus allopurinol for hyperuricemia].
Medizinische Monatsschrift fur Pharmazeuten 20061001
-
Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs.
Journal of clinical pharmacology 20060801
-
Febuxostat for prevention of gout attacks.
Issues in emerging health technologies 20060801
-
Gout's not just for the gluttonous.
The Johns Hopkins medical letter health after 50 20060601
-
New developments in clinically relevant mechanisms and treatment of hyperuricemia.
Current rheumatology reports 20060601
-
Is febuxostat a more effective treatment for hyperuricemia and gout than allopurinol?
Nature clinical practice. Rheumatology 20060501
-
Febuxostat versus allopurinol for gout.
The New England journal of medicine 20060406
-
Febuxostat versus allopurinol for gout.
The New England journal of medicine 20060406
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20060401
-
Newer therapeutic approaches: gout.
Rheumatic diseases clinics of North America 20060201
-
[Gout].
Revue medicale suisse 20060111
-
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Journal of clinical pharmacology 20060101
-
A concise history of gout and hyperuricemia and their treatment.
Arthritis research & therapy 20060101
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
Arthritis research & therapy 20060101
-
Advances in the management of gout and hyperuricaemia.
Scandinavian journal of rheumatology 20060101
-
Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
Clinical pharmacokinetics 20060101
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20060101
-
Pathophysiology, clinical presentation and treatment of gout.
Drugs 20060101
-
Metabolic diseases: gout.
Clinics in dermatology 20060101
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
The New England journal of medicine 20051208
-
Febuxostat--treatment for hyperuricemia and gout?
The New England journal of medicine 20051208
-
An update on the treatment options for gout and calcium pyrophosphate deposition.
Expert opinion on pharmacotherapy 20051101
-
Febuxostat (Teijin/Ipsen/TAP).
Current opinion in investigational drugs (London, England : 2000) 20051101
-
Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Expert opinion on investigational drugs 20050701
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20050601
-
Recent advances in the management of gout and hyperuricemia.
Current opinion in rheumatology 20050501
-
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Life sciences 20050304
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Arthritis and rheumatism 20050301
-
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment.
American journal of therapeutics 20050101
-
Y-700 [1-[3-Cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid]: a potent xanthine oxidoreductase inhibitor with hepatic excretion.
The Journal of pharmacology and experimental therapeutics 20041101
-
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Nucleosides, nucleotides & nucleic acids 20041001
-
PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment.
Nucleosides, nucleotides & nucleic acids 20041001
-
Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Nucleosides, nucleotides & nucleic acids 20041001
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20040901
-
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Current rheumatology reports 20040601
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20031201
-
An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
The Journal of biological chemistry 20030117
-
[Development antihyperuricemic candidates].
Nihon rinsho. Japanese journal of clinical medicine 20030101
-
Gateways to clinical trials.
Methods and findings in experimental and clinical pharmacology 20030101